Fosun International expects to report a net loss of approximately 21.5 billion to 23.5 billion RMB for the fiscal year 2025, mainly due to concentrated asset impairments and value reassessments.
Management stated that this move is an active risk-clearing measure that will help improve asset quality and ensure future financial performance more accurately reflects the operating situation.
Strategic Focus Shifts to Core Industries
In recent years, Fosun has continuously divested from non-core assets and has shifted its strategic focus to core industries such as healthcare, insurance, tourism, consumer products, and advanced manufacturing.
Analysts believe that as the influence of traditional businesses such as real estate gradually diminishes, the company's growth momentum will increasingly come from innovative drugs, insurance services, and global consumer brands.
Divergence in Investment Institutions' Views
Regarding institutional opinions, Guotai Junan Securities initiated coverage of Fosun International with an "overweight" rating, believing the company's profitability will gradually be released.
Goldman Sachs maintained a "neutral" rating but raised the target price, considering that the listing of innovative drugs, insurance business growth, and improvements in the manufacturing business will become important sources of future profits.
Long-term Goals Remain Unchanged
Fosun's management stated that in the next three to five years, they will continue to reduce debt and optimize the financial structure, aiming to reduce the group's debt scale to about 60 billion RMB while striving to upgrade overseas credit ratings to investment grade.
On the basis of gradually releasing profits, the company plans to enhance shareholder returns and promote long-term growth.
